Leavell Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Leavell Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,401	Closed	-$1.44M	–	412
2021 Q2	$1.44M	Hold	9,401	–	–	0.12%	168
2021 Q1	$1.44M	Hold	9,401	–	–	0.12%	168
2020 Q4	$1.47M	Sell	9,401 -11	-0.1%	-$1.41K	0.13%	162
2020 Q3	$1.08M	Hold	9,412	–	–	0.09%	178
2020 Q2	$1.06M	Hold	9,412	–	–	0.1%	174
2020 Q1	$845K	Hold	9,412	–	–	0.1%	172
2019 Q4	$1.02M	Hold	9,412	–	–	0.1%	183
2019 Q3	$922K	Sell	9,412 -38	-0.4%	-$4.28K	0.09%	190
2019 Q2	$1.24M	Hold	9,450	–	–	0.13%	159
2019 Q1	$1.28M	Hold	9,450	–	–	0.14%	152
2018 Q4	$920K	Hold	9,450	–	–	0.12%	178
2018 Q3	$1.31M	Sell	9,450 -200	-2%	-$25.1K	0.14%	155
2018 Q2	$1.2M	Hold	9,650	–	–	0.14%	158
2018 Q1	$1.08M	Sell	9,650 -200	-2%	-$23.9K	0.13%	170
2017 Q4	$1.18M	Hold	9,850	–	–	0.14%	160
2017 Q3	$1.38M	Hold	9,850	–	–	0.17%	148
2017 Q2	$1.2M	Sell	9,850 -1,650	-14%	-$192K	0.15%	152
2017 Q1	$1.39M	Buy	11,500 +500	+5%	+$64.5K	0.18%	131
2016 Q4	$1.35M	Sell	11,000 -2,200	-17%	-$269K	0.19%	134
2016 Q3	$1.62M	Hold	13,200	–	–	0.24%	118
2016 Q2	$1.54M	Sell	13,200 -100	-0.8%	-$14.2K	0.23%	121
2016 Q1	$1.85M	Sell	13,300 -1,200	-8%	-$176K	0.28%	103
2015 Q4	$2.77M	Sell	14,500 -50	-0.3%	-$8.73K	0.41%	70
2015 Q3	$2.27M	Sell	14,550 -125	-0.9%	-$22.8K	0.36%	83
2015 Q2	$2.65M	Sell	14,675 -1,190	-8%	-$205K	0.41%	70
2015 Q1	$2.75M	Hold	15,865	–	–	0.42%	70
2014 Q4	$2.94M	Sell	15,865 -2,000	-11%	-$371K	0.45%	62
2014 Q3	$2.96M	Sell	17,865 -1,850	-9%	-$304K	0.47%	61
2014 Q2	$3.08M	Sell	19,715 -3,200	-14%	-$505K	0.49%	58
2014 Q1	$3.49M	Hold	22,915	–	–	0.58%	45
2013 Q4	$3.04M	Sell	22,915 -1,000	-4%	-$120K	0.51%	57
2013 Q3	$2.78M	Sell	23,915 -1,850	-7%	-$203K	0.5%	60
2013 Q2	$2.38M	Buy	+25,765	New	+$2.48M	0.44%	63

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Leavell Investment Management's ALXN Position: Q3 2021 in Review

Leavell Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 9,401 shares — an estimated $1.44M sold.

Leavell Investment Management first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $3.49M in Q1 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Leavell Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Leavell Investment Management sold 9,401 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.44M.
Leavell Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
Leavell Investment Management's Alexion Pharmaceuticals position peaked at $3.49M in Q1 2014.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Leavell Investment Management's 13F filing for Q3 2021, filed 26 Oct 2021.